Suchergebnisse - "talazoparib"

PubPharm (308)

21

Hematological Toxicities with PARP Inhibitors in Prostate Cancer : A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials

enthalten in: Cancers | 2023

von Bowling, G. | Swargaloganathan, P. | Heintz, C. | +4

22

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer : Results of a Phase II Study

enthalten in: The oncologist | 2023

von Litton, J. | Beck, J. | Jones, J. | +13

23

Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis

enthalten in: European urology oncology | 2023

von Fazekas, T. | Széles, �. | Teutsch, B. | +8

24

Functional inhibition of RECQL5 helicase elicits non-homologous end joining response and sensitivity of breast cancers to PARP inhibitor

enthalten in: The international journal of biochemistry & cell biology | 2023

von Philip, K. | Dutta, K. | Chakraborty, S. | +1

25

Talazoparib (Talzenna) for prostate cancer

enthalten in: The Medical letter on drugs and therapeutics | 2023

26

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma : dose-finding results from phase Ib of the JAVELIN PARP MEKi trial

enthalten in: ESMO open | 2023

von Rodon Ahnert, J. | Tan, D. | Garrido-Laguna, I. | +13

27

Talazoparib for newly diagnosed prostate cancer associated with significant risk reduction of disease progression

enthalten in: Cancer | 2023

von Nierengarten, M.

28

Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer : Overcoming Challenges in Genetic Testing and Clinical Considerations When Using Talazoparib

enthalten in: Clinical breast cancer | 2023

von Brugioni, E. | Cathcart-Rake, E. | Metsker, J. | +3

29

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2) : a randomised, placebo-controlled, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Agarwal, N. | Azad, A. | Carles, J. | +18

CommentIn: Lancet. 2023 Jul 22;402(10398):266-267. - PMID 37285866

30

Clinical efficacy of PARP inhibitors in breast cancer

enthalten in: Breast cancer research and treatment | 2023

von Pandya, K. | Scher, A. | Omene, C. | +7